C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies

Kidney Medicine 2026 Open access

Read full text
Authors: Mahtab Mashayekhi, Jonathan E. Zuckerman, Jonathan Barratt, Richard J. Glassock, Fernando Caravaca-Fontán, Raymond K. Hsu, Arun Rajasekaran, Edgar V. Lerma, Sahibzadi Mahrukh Noor, Amir Abdipour, Sayna Norouzi
DOI: 10.1016/j.xkme.2026.101258
Cited by: 3
References: 71

Abstract

C3 glomerulopathy (C3G) is characterized by prominent deposition of complement component C3 in the kidney glomeruli, leading to glomerular inflammation. C3G is a rare and complex pattern of injury caused by dysregulation of the alternative pathway of complement system and occurs in both children and adults. It can happen because of genetic and acquired factors. Kidney biopsy is the gold standard for diagnosing C3G. About 50% of cases progress to kidney failure, and traditional treatment strategies, including immunosuppression and supportive care, have demonstrated variable efficacy. In this review, we aim to provide a comprehensive overview of pathophysiology, clinical presentations, and diagnostic criteria of C3G. Additionally, we will discuss current treatment guidelines and ongoing clinical trials.

Fields of Study & Subjects

Complement system in diseases Coagulation Bradykinin Polyphosphates and Angioedema Amyloidosis: Diagnosis Treatment Outcomes

Publication details

Journal / source
Kidney Medicine
Publisher
Elsevier BV
Volume
8
Issue
3
Pages
101258–101258
Publication date
10 January 2026
Language
EN